section name header

Pronunciation

byoo-DESS-oh-nide

Classifications

Therapeutic Classification: corticosteroids

Pharmacologic Classification: corticosteroids

Indications

REMS


Action

  • Potent, locally acting anti-inflammatory and immune modifier.
Therapeutic effects:
  • Decrease in symptoms of allergic rhinitis.

Pharmacokinetics

Absorption: 34%; action is primarily local following nasal use.

Distribution: Widely distributed to tissues.

Protein Binding: 80–90%.

Metabolism/Excretion: Rapidly and extensively metabolized by the liver; 67% excreted in urine; 33% in feces.

Half-Life: 2–3 hr.

Time/Action Profile

(improvement in symptoms)

ROUTEONSETPEAKDURATION
Intranasal1–2 days2 wkunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

EENT: epistaxis, nasal burning, nasal irritation, nasopharyngeal fungal infection, pharyngitis, sneezing

GI: dry mouth, dyspepsia

Endo: adrenal suppression (increased dose, long-term therapy only), growth (children)

Resp: bronchospasm, cough

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Rhinocort Allergy

Canadian Brand Names

Rhinocort Aqua